Vaccinex is a privately-held, clinical-stage biotechnology company developing an antibody against a novel immunotherapy target to modulate immune response to solid tumors and neurodegenerative diseases. Phase 1 trials in solid tumor patients and multiple sclerosis completed; plan for a Phase 1/2 trial in combination with immune checkpoint inhibitor for cancer and a Phase 2 trial of single agent in Huntington’s Disease.

Read More